Jyong Biotech Ltd. Ordinary Shares Cash Flow-to-Debt Ratio
Jyong Biotech Ltd. Ordinary Shares cash flow-to-debt ratio. Jyong Biotech Ltd. Ordinary Shares (MENS) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2024, meaning its operating cash flow of $-913.00K could theoretically repay 0% of its total liabilities ($42.88 Million) in one year. See MENS FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jyong Biotech Ltd. Ordinary Shares (2020–2025)
Cash flow-to-debt ratio of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2025. Historical debt coverage capacity for Jyong Biotech Ltd. Ordinary Shares across 6 annual periods. Also explore net asset growth rate of Jyong Biotech Ltd. Ordinary Shares to track the company's year-over-year net asset growth rate.
Jyong Biotech Ltd. Ordinary Shares Cash Flow-to-Debt Ratio by Year (2020–2025)
Jyong Biotech Ltd. Ordinary Shares cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Jyong Biotech Ltd. Ordinary Shares. For the full cash flow conversion analysis, see Jyong Biotech Ltd. Ordinary Shares (MENS) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-3.04 Million | $45.68 Million | ▲ +21.2% |
| 2024 | -0.08x | $-3.62 Million | $42.88 Million | ▼ -37.5% |
| 2023 | -0.06x | $-2.60 Million | $42.32 Million | ▲ +20.6% |
| 2022 | -0.08x | $-2.97 Million | $38.38 Million | ▼ -27.8% |
| 2021 | -0.06x | $-1.98 Million | $32.76 Million | ▼ -78.6% |
| 2020 | -0.03x | $-1.09 Million | $32.05 Million | — |